tiprankstipranks
Inhibitor Therapeutics Inc. (INTI)
OTHER OTC:INTI
US Market
INTI
Inhibitor Therapeutics
RESEARCH TOOLSreports

Inhibitor Therapeutics (INTI) Income Statement

30 Followers

Inhibitor Therapeutics Income Statement

Last quarter (Q4 2025), Inhibitor Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Inhibitor Therapeutics's net income was $-1.30M. See Inhibitor Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 3.43M$ 3.66M$ 3.40M$ 657.93K$ 325.39K
Depreciation and Amortization
$ 0.00$ 3.66M$ 3.40M$ 657.93K$ 325.39K
EBITDA
$ -3.43M$ 318.00K$ 378.84K$ -74.00$ -325.00K
Operating Income
$ -3.43M$ -3.66M$ -3.40M$ -658.00K$ -325.00K
Other Income/Expenses
$ 126.32K$ 318.21K$ 378.84K$ 12.82M$ 26.76K
Pretax Income
$ -3.30M$ -3.34M$ -3.03M$ 12.16M$ -299.00K
Net Income
$ -3.30M$ -3.34M$ -3.03M$ 12.11M$ -299.00K
Per Share Metrics
Basic EPS
$ -0.02$ -0.02$ -0.02$ 0.03$ 0.00
Diluted EPS
$ -0.02$ -0.02$ -0.02$ 0.03$ 0.00
Weighted Average Shares Outstanding
 172.51M 172.26M 151.31M 366.18M 376.25M
Weighted Average Shares Outstanding (Diluted)
 172.51M 172.26M 171.95M 367.78M 376.25M
Currency in USD

Inhibitor Therapeutics Earnings and Revenue History